Atara Biotherapeutics (ATRA) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atara Biotherapeutics (ATRA) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 40.1% versus a loss of 64.4%. Over five years, MIST leads with a -87.9% price change compared with -97.5% for ATRA. Atara Biotherapeutics is the larger company by market cap ($92.6 million vs $88.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | MIST |
|---|---|---|
| Share price | $9.23 | $0.7121 |
| Market cap | $92.65M | $88.66M |
| 1-day change | -1.49% | -5.96% |
| YTD return | -48.20% | -64.75% |
| 1-year return | -40.05% | -64.39% |
| 5-year return | -97.52% | -87.93% |
| Forward P/E | 5.97 | — |
| EPS (TTM) | $-1.26 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.15 | $3.06 |
| 52-week low | $3.92 | $0.709 |
| Distance from 52-week high | -51.79% | -76.73% |
| Analyst consensus | buy | none |
| Avg. price target upside | +48.10% | +722.92% |
| Average volume | 53.79K | 1.40M |
| Shares outstanding | 10.04M | 124.50M |
| Employees | 10 | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRA has outperformed MIST by 24.3 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Healthcare · Biotechnology · 10 employees
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Healthcare · Biotechnology · 38 employees
ATRA vs MIST FAQ
Which is bigger, Atara Biotherapeutics or Milestone Pharmaceuticals?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $92.65M compared with $88.66M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, ATRA or MIST?
ATRA returned -40.05% over the past 12 months, compared with -64.39% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Milestone Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.